Navigation Links
Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Date:11/18/2009

BALTIMORE, Nov. 18 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Yale University and Southern Research Institute for the development of Bithionol for cancer treatment. Scientists from Yale and Southern Research found that Bithionol, a drug available for helminthic infections, shows activity against solid cancerous tumors and has the potential to treat melanoma, prostate, breast and lung cancer, among other cancers.

Their research found that Bithionol is an Autotaxin inhibitor that is expected to be useful in treating various types of cancer. By inhibiting Autotaxin (ATX), a prometastatic enzyme, Bithionol inhibits myriad of biological activities, including angiogenesis and the promotion of cell growth, survival, and differentiation. ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies.

Under the terms of the agreement, Champions will have exclusive rights and be responsible for the further development of Bithionol for all oncology indications. Yale and Southern Research will receive an upfront payment and will be eligible to receive milestone payments and royalties. Additionally, the parties have agreed upon certain terms favorable to developing world markets.

Champions will use its predictive Biomerk Tumorgraft(TM) platform to assess the efficacy of the compound -- alone and in combination with other compounds -- to determine its optimal application and enable efficient clinical development. Upon successful results, Champions will move the compound forward into human clinical trials. "The benefits of our predictive Tumorgraft(TM) evaluation ar
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
2. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
5. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
6. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
7. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
8. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
9. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
10. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... R.I. (Brown University) -- The discovery 30 years ago ... an explosion of nanotechnology research. Now, there appears to ... from Brown University, Shanxi University and Tsinghua University in ... atoms forms a hollow molecular cage similar to a ... boron cage structurepreviously only a matter of speculationdoes indeed ...
Breaking Biology Technology:Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) today announced ... scheduled to present at the Rodman & Renshaw,10th Annual ... Tuesday, November 11th, 2008 at 2:50 p.m. Eastern Time ... 2008 at the,Palace Hotel in New York., The ...
... Driven by the emergence of innovative technologies ... and proteomics, world market for drug discovery ... by 2012. Despite the heavy costs involved ... pharmaceutical research and development are reaching new ...
... of Wisconsin-Madison engineers and physicists have developed a method ... that could lay the foundation for faster flexible electronics. ... electronic devices. Silicon thin films could be the basis ... inducing strain into the silicon increases device speed, yet ...
Cached Biology Technology:Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 2Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 3Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts 4Stretching silicon: A new method to measure how strain affects semiconductors 2
(Date:7/14/2014)... of Kansas scientists to the discovery and description of ... collections specimen, which turned out to represent a new genus ... ripidiine wedge beetle from Borneo is discussed in a recent ... . , The holotype male, and only known specimen ... in Borneo but subsequent to this it was transferred among ...
(Date:7/14/2014)... environment manage much better in the struggle for survival ... A world without bees would be a whole lot ... million to 1 billion Danish kroner are earned annually ... and pollinating a wide range of crops from apples ... the world are under pressure from pesticides, mites, viruses, ...
(Date:7/14/2014)... The Roquin protein, discovered in 2005, controls T-cell ... certain mRNAs. In doing so, it helps to ... the body,s own structures that can lead to ... Autoimmune diseases affect between five and ten per ... a result of complex environmental influences when a ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Best for bees to be stay-at-homes 2Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2
... Since the 1960s, psychiatrists have been hunting for substances ... high levels to produce the symptoms associated with schizophrenia. ... might be related to the hallucinogens phencyclidine (PCP) or ... of psychotic symptoms in schizophrenia. This "auto-intoxication" hypothesis led ...
... March 14, 2013 In the largest ever ... genetics company, identified 20 new genetic associations for myopia, ... in the study, which was specific to individuals of ... data and survey responses from more than 50,000 23andMe ...
... to feed, some whales throw their jaws wide and engulf ... along with their mouths agape (ram or skim feeding), yet ... whales, mouths to filter nutrition from the ocean: baleen. Alexander ... how the hairy substance actually traps morsels of food. ,The ...
Cached Biology News:The mysterious GRIN3A and the cause of schizophrenia 223andMe identifies multiple genetic factors impacting development of nearsightedness 2Whale's streaming baleen tangles to trap food 2
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Fetal Calf Serum Replacement (Bistec) serum...
...
Biology Products: